Advanced search
Publication Cover
Acta Oto-Laryngologica Volume 142, 2022 - Issue 1
Submit an article Journal homepage
198
Views
1
CrossRef citations to date
0
Altmetric
Otoneurology

Clinical manifestations and genetic analysis of a family with neurofibromatosis type 2

Victoria Y. Wanga School of Medicine, Case Western Reserve University, Cleveland, OH, USA
,
Te-Yi Liub Department of Otolaryngology, Hsinchu Cathay General Hospital, Hsinchu, Taiwan
,
Te-Yung Fangc Department of Otolaryngology, Cathay General Hospital, Taipei, Taiwan;d School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan
,
Ya-Hui Chene Department of Medical Research, Cathay General Hospital, Taipei, Taiwan
,
Chi-Jung Huange Department of Medical Research, Cathay General Hospital, Taipei, Taiwan;f Department of Biochemistry, National Defense Medical Center, Taipei, TaiwanCorrespondence[email protected]
&
Pa-Chun Wangc Department of Otolaryngology, Cathay General Hospital, Taipei, Taiwan;d School of Medicine, Fu-Jen Catholic University, New Taipei City, TaiwanCorrespondence[email protected]
Pages 36-42 | Received 14 Sep 2021, Accepted 21 Oct 2021, Published online: 16 Dec 2021

References

  • Smith MJ, Wallace AJ, Bowers NL, et al. Frequency of SMARCB1 mutations in familial and sporadic schwannomatosis. Neurogenetics. 2012;13(2):141–145.
  • Evans DG, Moran A, King A, et al. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol. 2005;26(1):93–97.
  • Sperfeld AD, Hein C, Schröder JM, et al. Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2. Brain. 2002;125(5):996–1004.
  • Chen H, Xue L, Wang H, et al. Differential NF2 gene status in sporadic vestibular schwannomas and its prognostic impact on tumour growth patterns. Sci Rep. 2017;7(1):5470.
  • Huang JS, Huang CJ, Chen SK, et al. Associations between VHL genotype and clinical phenotype in familial von Hippel-Lindau disease. Eur J Clin Invest. 2007;37(6):492–500.
  • Yang C, Huang CH, Cheong ML, et al. Unambiguous molecular detections with multiple genetic approach for the complicated chromosome 22q11 deletion syndrome. BMC Med Genet. 2009;10(1):16.
  • Kluwe L, Nygren AO, Errami A, et al. Screening for large mutations of the NF2 gene. Genes Chromosomes Cancer. 2005;42(4):384–391.
  • Martínez-Glez V, Franco-Hernández C, Lomas J, et al. Multiplex ligation-dependent probe amplification (MLPA) screening in meningioma. Cancer Genet Cytogenet. 2007;173(2):170–172.
  • Parry DM, Eldridge R, Kaiser-Kupfer MI, et al. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet. 1994;52(4):450–461.
  • Mautner VF, Lindenau M, Baser ME, et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery. 1996;38(5):880–886.
  • Evans DG. Neurofibromatosis 2 [bilateral acoustic neurofibromatosis, Central neurofibromatosis, NF2, neurofibromatosis type II]. Genet Med. 2009;11(9):599–610.
  • Moyhuddin A, Baser ME, Watson C, et al. Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. J Med Genet. 2003;40(6):459–463.
  • Bijlsma EK, Merel P, Fleury P, et al. Family with neurofibromatosis type 2 and autosomal dominant hearing loss: identification of carriers of the mutated NF2 gene. Hum Genet. 1995;96(1):1–5.
  • Cui YX, Xia XY, Huang TT, et al. Mutation analysis of NF2 gene and clinical investigation in a chinese family with neurofibromatosis type II. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2010;27(6):688–691.
  • Kuo HC, Chen SR, Jung SM, et al. Neurofibromatosis 2 with peripheral neuropathies: electrophysiological, pathological and genetic studies of a Taiwanese family. Neuropathology. 2010;30(5):515–523.
  • Chen HJ, Teng HC, Li SS. Molecular characterization of germline mutations in neurofibromatosis 2 in two families. J Formos Med Assoc. 1998;97(12):869–872.
  • Plotkin SR, Merker VL, Muzikansky A, et al. Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients. Otol Neurotol. 2014;35(1):e50–e56.
  • Emmanouil B, Houston R, May A, et al. Progression of hearing loss in neurofibromatosis type 2 according to genetic severity. Laryngoscope. 2019;129(4):974–980.
  • Halliday D, Emmanouil B, Pretorius P, et al. Genetic severity score predicts clinical phenotype in NF2. J Med Genet. 2017;54(10):657–664.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.